Fig. 3.

Pattern of active vitamin D administration in the examined calendar quarters across eight 10-year age increments in 139,328 hemodialysis patients from July 2001 to June 2001. (Left panel) Proportion of hemodialysis patients who received any dose of an active vitamin D compound (paricalcitol 58%, calcitriol 2%, doxercalciferol <1%, and no active vitamin D 38%) in 43,974 African-American and 95,354 non-African-American hemodialysis patients. (Right panel) The 3-month average administered paricalcitol dose (mean ± SD) among 49,674 hemodialysis patients (including 19,918 African Americans) who received any dose of paricalcitol during the calendar quarter.